Cleared Traditional

K770888 - POMERANTZEFF EQUATOR PLUS CAMERA

K770888 is the FDA 510(k) clearance for POMERANTZEFF EQUATOR PLUS CAMERA by Medical Instrument Research Assoc., Inc.. It is a Class 2 Ophthalmic device (product code HKI) cleared through the Traditional 510(k) pathway after a 18-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1977
Decision
18d
Days
Class 2
Risk

K770888 is an FDA 510(k) clearance for the POMERANTZEFF EQUATOR PLUS CAMERA. Classified as Camera, Ophthalmic, Ac-powered (product code HKI), Class II - Special Controls.

Submitted by Medical Instrument Research Assoc., Inc. (Mchenry, US). The FDA issued a Cleared decision on June 3, 1977 after a review of 18 days - a notably fast clearance cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.1120 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Medical Instrument Research Assoc., Inc. devices

Submission Details

510(k) Number K770888 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 16, 1977
Decision Date June 03, 1977
Days to Decision 18 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
92d faster than avg
Panel avg: 110d · This submission: 18d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code HKI Camera, Ophthalmic, Ac-powered
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 886.1120
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.